International Kidney Cancer Symposium (IKCS) 2015

High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment

By

Jason Hoffman, PharmD, RPh

Publish Date November 8, 2015

High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.

Study Assessing Dalantercept Plus Axitinib for Advanced Clear Cell RCC

By

Jason Hoffman, PharmD, RPh

Publish Date November 8, 2015

Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).

Study Supports Standard Sequence of Sunitinib Followed by Everolimus in mRCC

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.

Axitinib Treatment May Result in Higher Drug Costs Than Everolimus for Advanced RCC

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

Axitinib treatment may result in higher drug costs compared with everolimus.

Adding TRC105 to Axitinib May Improve PFS for Clear Cell RCC

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.

Alternative Axitinib Dose Escalation Schema May Improve Tolerability in mRCC

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).

Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/Sorafenib

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).

Almost Half of All Patients With mRCC Defer Frontline Systemic Therapy

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.

Management of Immune-Related Adverse Events

By

Jason Hoffman, PharmD, RPh

Publish Date November 7, 2015

Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.

First-line Sunitinib, Pazopanib Have Similar Efficacy for mRCC in Population-based Setting

By

Jason Hoffman, PharmD, RPh

Publish Date November 6, 2015

In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).